Endocrinology

The device supplants Abbott's own 10-day Libre system as the longest-lasting self-applied continuous glucose monitoring system on the US market.

According to a new study, young cancer survivors are at a 73% higher risk for endocrine disease.

The paradigm of obesity is complex and requires a multi-disciplinary approach, but it is one of the most gratifying experiences for both the physicians and patient when they see the results of weight loss.

Positive data for the add-on therapy for patients with type 2 diabetes and chronic kidney disease will be presented at an upcoming medical meeting.

Why can it be difficult to get diabetes patients to an eye exam? One physician offers some insight. 

The Cleveland Clinic’s pioneer of minority programs plans to end health disparity.

To the knowledge of researchers, this is the first demonstration to show C3a can stimulate basal deposit production by normal human RPE cells.

How can we help our diabetes patients break out of the negative feedback loop and find positivity? Edward C. Chao, DO, shares 3 simple steps. 

Peter Toth, MD, spoke about the importance of noting elevated triglycerides in patients at risk for cardiovascular conditions.

The study revealed for the first time that triglycerides can be utilized as an independent predictor of cardiovascular risk—a landmark moment.

New research suggests cirrhosis, not HCV status, is the reason diabetes rates are higher among HCV-infected patients.

Targeting metabolism with therapies such as metformin has shown in clinical settings to affect aging itself. In IPF, it could influence the rate of aging as well.

AF is associated with major disease burden, predominately in the form of cardiovascular comorbidities. As a direct oral anti-coagulant, rivaroxaban has been a proven inhibitor of ischemic stroke risks in patients with AF.

The poster presentations included a meta-analysis of 17 studies analyzing the cost-effectiveness and performance of the CGM system and a real-world examination of the trends its use.

Tim Dunn, PhD, discussed the benefits that the Freestyle Libre continuous glucose monitoring system provides for both the patients and providers

In a comparison of canagliflozin to other SGLT-2 inhibitors and anti-hyperglycemic therapies, the drug was found to decrease hospitalization from heart failure risk, and carry no extra risk for leg or foot amputation.

Murray Stewart, MD, spoke about his research into the hormone leptin—a major player in appetite and metabolism, with much that's still misunderstood about it.

The addition of features such as Bluetooth and Wi-Fi connectivity, in addition to cloud-to-cloud integration, is essential to improving diabetes devices.

Across the 6-month duration of the trial, weight loss was maintained across all dose levels, with patients that had the lowest baseline leptin levels benefitting the most.

How telehealth-friendly devices could change standard of diabetes care — with the help of physicians, patients, and the overall health care system.

Patients spent 11.2% more time in their target glucose range, and hypoglycemia was reduced from 5.1% to 1.9% overall, and 5.7% to 0.7% overnight.

How some of the most recent trial analysis narrows the clinical scope of GLP-1 and SGLT-2 targeting therapies.

Grenye O'Malley, MD, spoke about study data on insulin pen priming for patients with type 1 diabetes, noting that 80% of patients reported priming frequently.

Cardiovascular disease is the leading cause of death in women. And yet, the crux of concern for disease risk is designated to male patients.

The FRESCA Medical, Inc system is designed to operate with less airflow, alleviating some of the complaints that arise with traditional CPAP systems for patients with obstructive sleep apnea.

Is there a relationship between polycystic ovary syndrome and diabetes? And if so, what are the variations in female patients?

The OPTIFAST meal replacement program resulted in better outcomes than the standard of care and a higher proportion of patients no longer meeting criteria for type 2 diabetes.

During the first 12 weeks of study, the investigated therapy had also reduced patient hypoglycemia event rates by 23% and low blood sugar event rates by 26% versus comparative therapy.

Despite several of these 2 medicines have proved to reduce cardiovascular risks, that has not been the case for all options, leading to confusion.

The Medtronic MiniMed 670G system was expanded for pediatric T1D patients, then reported positive real-world symptom management during ADA 2018.